- Stocks
- Pharma & Healthcare
- Unjha Formula
Unjha Formula share price
NSE: UNJHAFORPharma & HealthcareDrug Manufacturers - Specialty & Generic
Unjha Formula at a glance
With a market capitalisation of ₹8 Cr, it ranks 3984th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
Its return on equity was 13.0% in FY25. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹3 Cr (−8.3% year on year) and net profit ₹0 Cr (−59.0%), on a standalone basis. Promoters held 36.92% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹8 CrRank 3984 on NSE
- Price to book
- 3.11×FY25
- EPS (TTM)
- ₹1.05to Q1 FY27
- ROE
- 13.0%FY25
- ROCE
- 16.9%FY25
- Debt to equity
- 0FY25
- Net profit margin
- 2.9%FY25
- Book value / share
- ₹7.01FY25
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Unjha Formula quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹4 Cr | ₹4 Cr | ₹2 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹3 Cr | ₹3 Cr |
| Revenue YoY | −20.6% | −32.3% | −46.5% | −8.6% | +13.5% | +17.3% | +38.4% | −8.3% |
| Net profit | −₹0 Cr | ₹0 Cr | −₹0 Cr | ₹0 Cr | ₹1 Cr | ₹0 Cr | −₹1 Cr | ₹0 Cr |
| Net profit YoY | — | −43.6% | — | −44.3% | — | +9.1% | — | −59.0% |
| Net margin | −2.9% | 5.9% | −17.3% | 10.8% | 19.1% | 5.4% | −22.6% | 4.8% |
| EPS | −₹0.25 | ₹0.50 | −₹0.91 | ₹0.90 | ₹1.83 | ₹0.53 | −₹1.66 | ₹0.35 |
Unjha Formula financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹11 Cr | ₹10 Cr | ₹14 Cr | ₹13 Cr | ₹19 Cr | ₹14 Cr |
| Operating profit | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹1 Cr |
| Net profit | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| EPS (₹) | ₹0.69 | ₹0.23 | ₹0.56 | ₹0.63 | ₹0.62 | ₹0.91 |
| Cash from operations | ₹0 Cr | −₹1 Cr | ₹0 Cr | −₹0 Cr | ₹1 Cr | −₹0 Cr |
| Total debt | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹3 Cr | ₹3 Cr |
Unjha Formula shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 36.92% | 36.92% | 36.92% | 36.92% | 36.92% | 36.92% |
| Non-institutions | 63.08% | 63.08% | 63.08% | 63.08% | 63.08% | 63.08% |
Unjha Formula vs peers
The listed Pharma & Healthcare companies nearest to Unjha Formula by market capitalisation.
Ask anything about Unjha Formula
Pivot answers on the live chart with evidence you can check, and tests strategies against UNJHAFOR's own history. Try: “Why has UNJHAFOR moved over the last three months?” · “Backtest a 50-day moving-average crossover on UNJHAFOR over five years” · “Compare UNJHAFOR with CTLLAB on margins and valuation”
Frequently asked questions about Unjha Formula
What is the market cap of Unjha Formula?
Unjha Formula's market capitalisation is ₹8 Cr (₹8 Cr) at the 22 Oct 2026 close, ranking 3984th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Unjha Formula?
Return on equity was 13.0% in FY25 and return on capital employed was 16.9% in FY25 (standalone figures).
Is Unjha Formula a debt-free company?
Unjha Formula is close to debt-free: its debt-to-equity ratio was 0 in FY25.
What were Unjha Formula's latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Unjha Formula reported revenue of ₹3 Cr, −8.3% year on year, and net profit of ₹0 Cr, −59.0% year on year.
What is the shareholding pattern of Unjha Formula?
As of 30 Jun 2026: promoters 36.92%, non-institutions 63.08%.
Who are Unjha Formula's competitors?
The listed Pharma & Healthcare companies closest to Unjha Formula by market cap are Clinitech Labor, Genomic Valley, Trinity League, Adline Chem Lab, Dr Lalchandani and Vivanza Bio.
Is Unjha Formula a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Unjha Formula's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on UNJHAFOR against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, standalone where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with U · all NSE stocks · this page as text